Literature DB >> 1958678

Oversizing of donor hearts: beneficial or detrimental?

M R Costanzo-Nordin1, Y L Liao, B B Grusk, E J O'Sullivan, R S Cooper, M R Johnson, K M Siebold, H J Sullivan, A H Heroux, J A Robinson.   

Abstract

To determine the effects of donor/recipient weight mismatch on allograft function and survival after orthotopic heart transplantation, we retrospectively compared the clinical and the hemodynamic characteristics of recipients weighing more than their donor ("undersized") with those of recipients weighing less than their donor ("oversized"). The median follow-up period was 24 months (range, 0 to 67 months). In 88 patients (59%) donor weight was 1% to 46% less than recipient weight (13.5 +/- 8.9 means +/- SD). In 61 patients (41%) donor weight exceeded recipient weight by 0% to 139% (20% +/- 23%). When recipient ideal body weight was used in the analysis, 75 patients (51%) were undersized by 1% to 59% (13% +/- 10%), and 72 patients (49%) were oversized by 0% to 67% (19% +/- 18%). Preoperative transpulmonary gradient, ventricular function, and exercise tolerance were similar in the two groups. The number and severity of episodes of rejection and infection after transplantation were also similar in the two groups 1, 6, and 12 months after transplantation. When recipient ideal weight was used in the analysis, right ventricular (RV) and left ventricular (LV) ejection fractions (EFs) were within normal limits (RVEF greater than 40%; LVEF greater than or equal to 45%) and similar in the two groups. When recipient actual weight was used in the analysis, the LVEF measured at 12 months after heart transplantation was higher in the oversized than in the undersized group (52 +/- 11 vs 46 +/- 10; p less than 0.05). Postoperative hemodynamic values and exercise tolerance were similar in the two groups regardless of whether recipient weight or ideal body weight were used in the analysis. Forty-six recipients died 0 to 46 months (median, 7 months) after orthotopic heart transplantation. In a Cox regression model, recipients with donor weight greater than recipient ideal weight had a significantly greater risk of death within the follow-up period than did recipients with donor weight less than recipient ideal weight (relative risk = 2.19; p less than 0.05). When percent donor weight/recipient ideal weight mismatch was used as a continuous variable, donor heart oversizing was negatively related to survival, independent of preoperative transpulmonary gradient values (p less than 0.05). In contrast to common belief, oversizing of donor hearts does not improve the outcome of orthotopic heart transplant recipients who have reversible preoperative pulmonary hypertension. Acceptance of undersized donor hearts is not detrimental to allograft function and recipient survival. Use of undersized donor hearts may maximize the use of critically scarce donor organs.

Entities:  

Mesh:

Year:  1991        PMID: 1958678

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  4 in total

1.  Why referred potential heart donors aren't used.

Authors:  P S Richards; K A Nelson; O H Frazier; B Radovancević; C Van Buren; J B Young
Journal:  Tex Heart Inst J       Date:  1993

2.  First-year clinical outcomes in gender-mismatched heart transplant recipients.

Authors:  Anne Jalowiec; Kathleen L Grady; Connie White-Williams
Journal:  J Cardiovasc Nurs       Date:  2012 Nov-Dec       Impact factor: 2.083

3.  Multiple risk factors before pediatric cardiac transplantation are associated with increased graft loss.

Authors:  Scott R Auerbach; Marc E Richmond; Jonathan M Chen; Ralph S Mosca; Jan M Quaegebeur; Linda J Addonizio; Daphne T Hsu; Jacqueline M Lamour
Journal:  Pediatr Cardiol       Date:  2011-09-04       Impact factor: 1.655

4.  Predictors of rehospitalization time during the first year after heart transplant.

Authors:  Anne Jalowiec; Kathleen L Grady; Connie White-Williams
Journal:  Heart Lung       Date:  2008 Sep-Oct       Impact factor: 2.210

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.